Academic Journal
View in EDS
HTML Full Text

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.

Bibliographic Details
Title: CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.
Authors: Solomon, Scott R., Powell, Bayard L., Koprivnikar, Jamie, Lai, Catherine, Male, Heather, Michaelis, Laura C., Newell, Laura F., Sanford, David, Jenkins, Jack, Zelaya, Amy, Coppola, Sheryl, Faderl, Stefan, Walter, Roland B.
Source: Cancers; Mar2024, Vol. 16 Issue 5, p915, 11p
Subject Terms: THERAPEUTIC use of antineoplastic agents, PHARMACEUTICAL arithmetic, HEMATOLOGIC malignancies, PATIENT safety, CREATININE, CLINICAL trials, ANTINEOPLASTIC agents, BLOOD collection, DESCRIPTIVE statistics, CYTARABINE, KIDNEY diseases, COMPARATIVE studies, URINE collection & preservation, DAUNOMYCIN
Geographic Terms: UNITED States
Abstract: Simple Summary: CPX-351 has been approved for the treatment of acute myeloid leukemia. Previous studies have indicated that dose adjustment is not warranted for patients with mild to moderate renal impairment. However, the effect of severe renal impairment on the use of CPX-351 has not been established. In this study, we evaluated CPX-351 in patients with normal renal function and in patients with moderate and severe renal impairment. We compared how CPX-351 moves through the body, as well as the safety of the drug, in these different patient groups. The results suggest that CPX-351 dose adjustment is not required for patients with hematologic malignancies with moderate or severe renal impairment. This open-label phase 1 study (clinicaltrials.gov, NCT03555955) assessed CPX-351 pharmacokinetics (PK) and safety in patients with hematologic malignancies with normal or impaired renal function. Patients were enrolled into three cohorts based on their creatinine clearance (CrCl): ≥90 mL/min (Cohort 1, normal renal function, n = 7), 30 to <59 mL/min (Cohort 2, moderate renal impairment, n = 8), or <30 mL/min (Cohort 3, severe renal impairment, n = 6). Patients received intravenous CPX-351 for initial induction; blood and urine samples were collected for PK analysis. The primary objective was to assess the PK parameters for cytarabine, daunorubicin, and their respective metabolites, arabinosyluracil (Ara-U) and daunorubicinol. Renal impairment did not significantly impact the cytarabine, daunorubicin, or daunorubicinol exposure, but it caused a slight increase in the Ara-U exposure. The CPX-351 side effect profile was similar in patients with impaired renal function compared to those with normal renal function. All the patients reported ≥1 treatment-emergent adverse event (TEAE), most commonly febrile neutropenia and nausea (57% each) and hyperglycemia (43%); no patients discontinued treatment due to TEAEs. These data suggest that CPX-351 dose adjustment is not required for patients with hematologic malignancies with moderate or severe renal impairment. [ABSTRACT FROM AUTHOR]
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edb&genre=article&issn=20726694&ISBN=&volume=16&issue=5&date=20240301&spage=915&pages=915-925&title=Cancers&atitle=CPX-351%20Pharmacokinetics%20and%20Safety%20in%20Adults%20with%20Hematologic%20Malignancies%20and%20Renal%20Function%20Impairment%3A%20Phase%201%20Trial.&aulast=Solomon%2C%20Scott%20R.&id=DOI:10.3390/cancers16050915
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: edb
DbLabel: Complementary Index
An: 175991739
RelevancyScore: 1007
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1007.03765869141
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Solomon%2C+Scott+R%2E%22&quot;&gt;Solomon, Scott R.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Powell%2C+Bayard+L%2E%22&quot;&gt;Powell, Bayard L.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Koprivnikar%2C+Jamie%22&quot;&gt;Koprivnikar, Jamie&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lai%2C+Catherine%22&quot;&gt;Lai, Catherine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Male%2C+Heather%22&quot;&gt;Male, Heather&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Michaelis%2C+Laura+C%2E%22&quot;&gt;Michaelis, Laura C.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Newell%2C+Laura+F%2E%22&quot;&gt;Newell, Laura F.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sanford%2C+David%22&quot;&gt;Sanford, David&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jenkins%2C+Jack%22&quot;&gt;Jenkins, Jack&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Zelaya%2C+Amy%22&quot;&gt;Zelaya, Amy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Coppola%2C+Sheryl%22&quot;&gt;Coppola, Sheryl&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Faderl%2C+Stefan%22&quot;&gt;Faderl, Stefan&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Walter%2C+Roland+B%2E%22&quot;&gt;Walter, Roland B.&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Cancers; Mar2024, Vol. 16 Issue 5, p915, 11p
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22THERAPEUTIC+use+of+antineoplastic+agents%22&quot;&gt;THERAPEUTIC use of antineoplastic agents&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22PHARMACEUTICAL+arithmetic%22&quot;&gt;PHARMACEUTICAL arithmetic&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22HEMATOLOGIC+malignancies%22&quot;&gt;HEMATOLOGIC malignancies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22PATIENT+safety%22&quot;&gt;PATIENT safety&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CREATININE%22&quot;&gt;CREATININE&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CLINICAL+trials%22&quot;&gt;CLINICAL trials&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22ANTINEOPLASTIC+agents%22&quot;&gt;ANTINEOPLASTIC agents&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22BLOOD+collection%22&quot;&gt;BLOOD collection&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22DESCRIPTIVE+statistics%22&quot;&gt;DESCRIPTIVE statistics&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CYTARABINE%22&quot;&gt;CYTARABINE&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22KIDNEY+diseases%22&quot;&gt;KIDNEY diseases&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22COMPARATIVE+studies%22&quot;&gt;COMPARATIVE studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22URINE+collection+%26+preservation%22&quot;&gt;URINE collection &amp; preservation&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22DAUNOMYCIN%22&quot;&gt;DAUNOMYCIN&lt;/searchLink&gt;
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22UNITED+States%22&quot;&gt;UNITED States&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Simple Summary: CPX-351 has been approved for the treatment of acute myeloid leukemia. Previous studies have indicated that dose adjustment is not warranted for patients with mild to moderate renal impairment. However, the effect of severe renal impairment on the use of CPX-351 has not been established. In this study, we evaluated CPX-351 in patients with normal renal function and in patients with moderate and severe renal impairment. We compared how CPX-351 moves through the body, as well as the safety of the drug, in these different patient groups. The results suggest that CPX-351 dose adjustment is not required for patients with hematologic malignancies with moderate or severe renal impairment. This open-label phase 1 study (clinicaltrials.gov, NCT03555955) assessed CPX-351 pharmacokinetics (PK) and safety in patients with hematologic malignancies with normal or impaired renal function. Patients were enrolled into three cohorts based on their creatinine clearance (CrCl): ≥90 mL/min (Cohort 1, normal renal function, n = 7), 30 to &lt;59 mL/min (Cohort 2, moderate renal impairment, n = 8), or &lt;30 mL/min (Cohort 3, severe renal impairment, n = 6). Patients received intravenous CPX-351 for initial induction; blood and urine samples were collected for PK analysis. The primary objective was to assess the PK parameters for cytarabine, daunorubicin, and their respective metabolites, arabinosyluracil (Ara-U) and daunorubicinol. Renal impairment did not significantly impact the cytarabine, daunorubicin, or daunorubicinol exposure, but it caused a slight increase in the Ara-U exposure. The CPX-351 side effect profile was similar in patients with impaired renal function compared to those with normal renal function. All the patients reported ≥1 treatment-emergent adverse event (TEAE), most commonly febrile neutropenia and nausea (57% each) and hyperglycemia (43%); no patients discontinued treatment due to TEAEs. These data suggest that CPX-351 dose adjustment is not required for patients with hematologic malignancies with moderate or severe renal impairment. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder&#39;s express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=175991739
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/cancers16050915
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 915
    Subjects:
      – SubjectFull: UNITED States
        Type: general
      – SubjectFull: THERAPEUTIC use of antineoplastic agents
        Type: general
      – SubjectFull: PHARMACEUTICAL arithmetic
        Type: general
      – SubjectFull: HEMATOLOGIC malignancies
        Type: general
      – SubjectFull: PATIENT safety
        Type: general
      – SubjectFull: CREATININE
        Type: general
      – SubjectFull: CLINICAL trials
        Type: general
      – SubjectFull: ANTINEOPLASTIC agents
        Type: general
      – SubjectFull: BLOOD collection
        Type: general
      – SubjectFull: DESCRIPTIVE statistics
        Type: general
      – SubjectFull: CYTARABINE
        Type: general
      – SubjectFull: KIDNEY diseases
        Type: general
      – SubjectFull: COMPARATIVE studies
        Type: general
      – SubjectFull: URINE collection & preservation
        Type: general
      – SubjectFull: DAUNOMYCIN
        Type: general
    Titles:
      – TitleFull: CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Solomon, Scott R.
      – PersonEntity:
          Name:
            NameFull: Powell, Bayard L.
      – PersonEntity:
          Name:
            NameFull: Koprivnikar, Jamie
      – PersonEntity:
          Name:
            NameFull: Lai, Catherine
      – PersonEntity:
          Name:
            NameFull: Male, Heather
      – PersonEntity:
          Name:
            NameFull: Michaelis, Laura C.
      – PersonEntity:
          Name:
            NameFull: Newell, Laura F.
      – PersonEntity:
          Name:
            NameFull: Sanford, David
      – PersonEntity:
          Name:
            NameFull: Jenkins, Jack
      – PersonEntity:
          Name:
            NameFull: Zelaya, Amy
      – PersonEntity:
          Name:
            NameFull: Coppola, Sheryl
      – PersonEntity:
          Name:
            NameFull: Faderl, Stefan
      – PersonEntity:
          Name:
            NameFull: Walter, Roland B.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: Mar2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 20726694
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Cancers
              Type: main
ResultId 1